F-1: Clearmind Files for Resale of 17M Shares, Secures $9M in Convertible Notes

Clearmind Medicine Inc. filed an F-1 registration statement for the resale of up to 17 million common shares by selling shareholders, following a $9 million convertible note financing to fund ongoing psychedelic medicine clinical trials.

Summary

• A registration statement for the resale of up to 17,016,694 common shares by identified selling shareholders has been filed.
• These shares include 16,970,241 common shares issued or issuable upon the conversion of convertible promissory notes and 46,453 common shares from equity award grants.
• The company entered into Securities Purchase Agreements (SPAs) on September 17, 2025, to issue convertible promissory notes with an aggregate principal amount of $10.0 million for a purchase price of $9.0 million.
• Initial gross proceeds of $0.5 million have been received from the First Initial Promissory Notes.
• An additional $1.75 million in gross proceeds is expected from the Second Initial Promissory Notes upon the SEC declaration of effectiveness for this registration statement.
• The company may request up to an additional $6.75 million in gross proceeds from the sale of additional Promissory Notes during subsequent three-month periods.
• Proceeds from the issuance of the promissory notes will be used for general corporate purposes, including operating expenses, research and development, working capital, future acquisitions, and general capital expenditures.
• The company will not receive any proceeds from the resale of common shares by the selling shareholders.
• Clearmind is a clinical pharmaceutical company engaged in Phase I/IIa clinical trials for MEAI, a novel psychedelic medicine targeting Alcohol Use Disorder (AUD), binge drinking, obesity, and metabolic disorders.
• Clinical trials for CMND-100 (MEAI for AUD) are ongoing in Israel and the United States at institutions including Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah-University Medical Center.
• Pre-clinical studies for MEAI have demonstrated anti-obesity effects and potential for treating other addictions like cocaine.
• The company operates as an emerging growth company and a foreign private issuer, benefiting from reduced public company reporting requirements.

Sentiment

Score: 4

Explanation: While the company has secured new financing and is making progress in clinical trials for promising drug candidates, the explicit 'going concern' warning from its auditor and the substantial dilution risk from the resale of shares by selling shareholders (from which the company receives no proceeds) significantly temper any positive sentiment. The geopolitical risks associated with its Israeli operations also add a layer of uncertainty.

Positives

• Secured $9.0 million in financing through convertible promissory notes, with potential for an additional $6.75 million, providing capital for operations and R&D.
• Ongoing Phase I/IIa clinical trials for CMND-100 (MEAI) for Alcohol Use Disorder (AUD) are progressing in multiple reputable institutions in Israel and the United States.
• Successful completion of pre-clinical studies for MEAI, demonstrating a well-tolerated safety profile in animals and promising effects on alcohol consumption, weight loss, and metabolic disorders.
• MEAI is identified as a neuroplastogen non-hallucinogenic molecule with potential broad applications beyond AUD and binge drinking, including obesity and other addictions.
• Received FDA and Israeli Ministry of Health approvals to initiate first-in-human Phase I/IIa clinical trials for CMND-100.
• Expanded clinical trial sites to include Tel Aviv Sourasky Medical Center and Hadassah-University Medical Center, enhancing research capacity.

Negatives

• The auditor's report for the fiscal year ended October 31, 2024, contains an explanatory paragraph raising substantial doubt about the entity's ability to continue as a going concern due to recurring losses from operations and lack of sufficient resources.
• There is significant potential for dilution to existing shareholders from the conversion of up to 16,970,241 common shares from promissory notes, and the future issuance of additional shares.
• The company will not receive any proceeds from the sale of the 17,016,694 common shares being registered for resale by selling shareholders.
• Management has broad discretion over the use of the net proceeds from the promissory notes, which may not align with shareholder expectations or produce positive returns.
• The pro forma accumulated deficit increased from $(27,192,000) to $(28,336,000) after giving effect to the full conversion of $2.5 million in promissory notes, indicating a negative impact on this specific equity component.

Risks

• The sale of a substantial amount of common shares (up to 17,016,694) by selling shareholders in the public market could adversely affect the prevailing market price of common shares and cause substantial dilution.
• Management has immediate and broad discretion over the use of net proceeds from the issuance and sale of the Promissory Notes, which may not be used effectively or in a manner that produces income.
• Operations are conducted in Israel, making the company susceptible to political, economic, and military conditions in the Middle East, including ongoing conflicts and regional instability.
• Military service call-ups in Israel could result in personnel absences, materially affecting business, prospects, financial condition, and results of operations.
• Insurance does not cover losses from events associated with the security situation in the Middle East or resulting operational disruptions, and government coverage may not be maintained or sufficient.
• Parties doing business with the company may decline to travel to Israel during unrest, forcing alternative arrangements.
• The company's ability to obtain and maintain regulatory approval for its product candidates is uncertain and requires extensive research and clinical trials.
• The company will require additional financing upon completion of Phase I/IIa studies to conduct further clinical trials.

Future Outlook

The company aims to develop and provide new treatments for mental health disorders, including AUD, binge drinking, and eating disorders, believing psychedelic therapies are the future for these indications. It intends to seek regulatory approval for MEAI through the FDA's 505(b)(1) path, which requires extensive clinical and nonclinical studies. Upon successful completion of Phase I/IIa studies, additional clinical trials will be required, subject to securing further financing. The company expects to use the net proceeds from the promissory notes for general corporate purposes, including operating expenses, research and development, working capital, future acquisitions, and general capital expenditures.

Management Comments

• Our goal is to develop and provide new type of treatments for mental health disorders, including AUD, binge drinking and eating disorders, where there is significant unmet need and lack of innovation.
• We see psychedelic therapies, which previously may have been overlooked or underused, as the future of treatment for a variety of indications.
• We believe that our solution for AUD can help solve one of the worlds biggest health problems, which costs the United States alone roughly $250 billion each year.
• Apart from potentially changing peoples lives, we believe that our treatment could potentially reduce the amount currently being spent on the consequences of AUD in the United States, Europe, India, China and other countries around the world.
• While determinations of safety and efficacy are solely within the authority of the FDA and comparable regulatory bodies, in pre-clinical studies, MEAI was well-tolerated by the tested animals.
• Although MEAI remains in development and is not cleared or approved by the FDA or similar foreign regulatory bodies, we believe that our drug candidate has the potential to change the lives of millions who struggle to drink in moderation.
• We believe that MEAI holds the potential to break the vicious binge-drinking cycle at the decision point to drink more alcohol, by potentially innervating neural pathways such as 5-HT1A that lead to sensible behavior.

Industry Context

The company operates in the emerging and rapidly evolving psychedelic medicine industry, focusing on novel treatments for mental health disorders like Alcohol Use Disorder (AUD), binge drinking, obesity, and metabolic disorders. This sector is characterized by significant unmet medical needs and a growing interest in alternative therapies, particularly neuroplastogens. The U.S. Surgeon General's advisory on alcohol and cancer risk highlights the substantial public health burden and economic cost of alcohol consumption, reinforcing the market opportunity for effective AUD treatments. Clearmind's development of MEAI as a non-hallucinogenic psychedelic positions it within a segment seeking to leverage the therapeutic potential of these compounds while potentially mitigating some of the regulatory and social challenges associated with hallucinogenic substances. The company's engagement with prominent research institutions like Yale and Johns Hopkins, and its pursuit of FDA 505(b)(1) approval, align with standard pharmaceutical development pathways in this innovative field.

Comparison to Industry Standards

• The company's engagement in Phase I/IIa clinical trials for CMND-100 for AUD at institutions like Yale School of Medicine and Johns Hopkins University School of Medicine aligns with the rigorous standards for early-stage drug development in the pharmaceutical industry.
• The pursuit of FDA's 505(b)(1) regulatory path for MEAI as a New Chemical Entity (NCE) is a standard approach for novel drugs, indicating a commitment to comprehensive safety and efficacy studies comparable to other biotech firms developing new compounds.
• Pre-clinical studies demonstrating MEAI's efficacy in reducing diet-induced obesity and improving glycemic control, as conducted with Professor Joseph Tam at the Hebrew University of Jerusalem, are consistent with the scientific rigor expected for novel therapeutic approaches in metabolic disorders.
• Research into MEAI's potential for treating substance addiction, including cocaine, conducted with Professor Gal Yadid at Bar Ilan University, reflects a strategic focus on addressing widespread health problems, similar to other companies exploring broad applications for their drug candidates.
• The auditor's 'going concern' warning is a significant red flag, indicating financial instability that is below the standard for established, profitable pharmaceutical companies, though not uncommon for early-stage clinical development companies that are pre-revenue.

Related Party Transactions

• Moshe Revach, husband of director Hila Kiron-Revach, received 12,000 common shares as an equity award grant outside of the Omnibus Stock Award Plan.
• AKA Optica Ltd., controlled by director Asaf Itzhaik, received 12,496 common shares as an equity award grant outside of the Omnibus Stock Award Plan.
• Yehonatan Shachar, a director, received 12,496 common shares as an equity award grant outside of the Omnibus Stock Award Plan.
• Alan Rootenberg, Chief Financial Officer, received 9,461 common shares as an equity award grant outside of the Omnibus Stock Award Plan.

Stakeholder Impact

• Shareholders face significant potential dilution from the resale of 17,016,694 common shares by selling shareholders, from which the company receives no proceeds. Existing shareholders' equity is also impacted by the pro forma increase in accumulated deficit.
• Investors (CLA Investors) have provided $9.0 million in financing through convertible notes, with potential for more, and will benefit from the resale of shares upon conversion. Their conversion options are protected by anti-dilution adjustments and a floor price.
• Employees are impacted as the company intends to use proceeds for general corporate purposes, including operating expenses and R&D, which supports continued employment and research activities.
• Patients are potential beneficiaries of the development of MEAI for AUD, binge drinking, obesity, and other mental health disorders, addressing significant unmet medical needs.
• Creditors face increased risk due to the company's 'going concern' warning, although the new financing provides some liquidity.

Next Steps

• SEC declaration of effectiveness for the F-1 registration statement.
• Issuance and sale of Second Initial Promissory Notes to CLA Investors.
• Potential future requests for CLA Investors to purchase additional Promissory Notes.
• Completion of Phase I/IIa clinical trials for CMND-100.
• Securing additional financing for subsequent clinical trials (Phase IIb/III).
• Further development of MEAI for obesity, metabolic disorders, and other addictions.
• Continued monitoring of the security situation in Israel and its potential impact on operations.

Key Dates

Recommendation

The company is in a high-risk, high-reward sector with promising pre-clinical results and ongoing clinical trials for MEAI. The recent capital raise provides necessary funding for operations and R&D. However, the 'going concern' warning from the auditor, significant potential for dilution from the resale of shares (from which the company receives no direct proceeds), and geopolitical risks associated with Israeli operations introduce substantial uncertainty. A 'hold' recommendation is appropriate for existing investors to monitor clinical trial progress and financial stability, while new investors should exercise extreme caution due to the high risk profile.

Keywords

Clearmind Medicine Inc., CMND, F-1, SEC filing, convertible notes, promissory notes, share resale, dilution, clinical trials, psychedelic medicine, MEAI, Alcohol Use Disorder, AUD, binge drinking, obesity, metabolic disorders, pharmaceutical, biotechnology, drug development, Nasdaq, Frankfurt Stock Exchange, Israel operations, going concern